• Home Dutch
  •  EN 
  • Employee login

Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database


Title:   Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
Investigators:  Hiddo Lambers Heerspink
Supervisor:  Dick de Zeeuw 
Summary:   The aim of this project is to establish a large database with data from various clinical trials that have been conducted in patients with type 2 diabetes at various stages of renal disease in order to assess and compare the relationship between different risk markers (e.g. blood pressure albuminuria HbA1c) and the risk for renal and cardiovascular disease progression. Another major aim of the database is to assess the relationship between short-term changes in biomarkers and their relationship with changes in long-term risk for renal / CV events. Since the database comprises the whole spectrum of renal disease progression, the comparative performance of (changes in) several biomarkers will be tested at different stages of disease. Currently, the database includes data from the following trials: BENEDICT, IRMA-2, LIFE-type 2 diabetes, RENAAL, IDNT, PLANET, VITAL, RADAR, SUN-micro and SUN-overt trials, ALTITUDE trials. 
Start:  1-01-2010 
End:   31-12-2016  

The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects